DÄ internationalArchiveReferences
References

cme

The Diagnosis and Graded Therapy of Atopic Dermatitis

Dtsch Arztebl Int 2014; 111(29-30): 509-20. DOI: 10.3238/arztebl.2014.0509

Werfel, T; Schwerk, N; Hansen, G; Kapp, A

1.Schmitz R, Atzpodien K, Schlaud M: Prevalence and risk factors of atopic diseases in German children and adolescents. Pediatr Allergy Immunol 2012; 23: 716–23. CrossRef MEDLINE
2. Werfel T, Claes C, Kulp W, Greiner W, von der Schulenburg JM: HTA-Bericht: Therapie der Neurodermitis. GMS Health Technol Assess 2006, www.egms.de
3.Heratizadeh A, Wichmann K, Werfel T: Food allergy and atopic dermatitis: how are they connected? Curr Allergy Asthma Rep 2011; 11: 284–91. CrossRef MEDLINE
4.Akdis CA, Akdis M, Bieber T, et al.: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 2006; 118: 152–69. CrossRef MEDLINE
5.Yaghmaie P, Koudelka CW, Simpson EL: Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol 2013; 131: 428–33 CrossRef MEDLINE PubMed Central
6.Kezic S, Novak N, Jakasa I, Jungersted JM, Simon M, Brandner JM, Middelkamp-Hup MA, Weidinger S: Skin barrier in atopic dermatitis. Front Biosci 2014; 19: 542–56. CrossRef MEDLINE
7.Irvine AD, McLean WH, Leung DY: Filaggrin mutations associated with skin and allergic diseases. N Engl J Med 2011; 365: 1315–27. CrossRef MEDLINE
8.Werfel T: The role of leukocytes, keratinocytes, and allergen-specific IgE in the development of atopic dermatitis. J Invest Dermatol 2009; 129: 1878–91. CrossRef MEDLINE
9.Pellerin L, Henry J, Hsu CY, et al.: Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin. J Allergy Clin Immunol 2013; 131: 1094–102. CrossRef MEDLINE
10. Muche-Borowski C, Kopp M, Reese I, Sitter H, Werfel T, Schäfer T: Allergy prevention. Dtsch Arztebl Int 2009; 106; 625–31. VOLLTEXT
11. Vestergaard C, Deleuran M: Advances in the diagnosis and therapeutic management of atopic dermatitis. Drugs 2014 74: 757–69. CrossRef MEDLINE
12.Dondi A, Ricci L, Neri I, Ricci G, Patrizi A: The switch from non-IgE-associated to IgE-associated atopic dermatitis occurs early in life. Allergy 2013; 68: 259–60. CrossRef MEDLINE
13.Tang TS, Bieber T, Williams HC: Does „autoreactivity“ play a role in atopic dermatitis? J Allergy Clin Immunol 2012; 129: 1209–15 CrossRef MEDLINE
14.Werfel T, Ballmer-Weber B, Eigenmann PA, Niggemann B, Rancé F, Turjanmaa K, Worm M: Eczematous reactions to food in atopic eczema: position paper of the EAACI and GA2LEN. Allergy 2007; 62: 723–28. CrossRef MEDLINE
15.Werfel T, Erdmann S, Fuchs T, et al.: Vorgehen bei vermuteter Nahrungsmittelallergie bei atopischer Dermatitis. J Dtsch Dermatol Ges 2009; 7: 265–71. MEDLINE
16.Kugler C: Ernährungstherapie beim atopischen Ekzem. Allergologie 2012; 34: 159–67. CrossRef
17.Heine G, Schnuch A, Uter W, Worm M: Information Network of Departments of Dermatology (IVDK); German Contact Dermatitis Research Group (DKG). Type-IV sensitization profile of individuals with atopic eczema: results from the Information Network of Departments of Dermatology (IVDK) and the German Contact Dermatitis Research Group (DKG). Allergy 2006; 61: 611–6. CrossRef MEDLINE
18.Thyssen JP, Linneberg A, Engkilde K, Menné T, Johansen JD: Contact sensitization to common haptens is associated with atopic dermatitis: new insight. Br J Dermatol 2012; 166: 1255–61. CrossRef MEDLINE
19.Turjanmaa K, Darsow U, Niggemann B, Rance F, Vanto T, Werfel T: EAACI/GA2LEN position paper: present status of the atopy patch test. Allergy 2006; 61: 1377–84. CrossRef MEDLINE
20.Werfel T, Aberer W, Augustin M, et al.: Neurodermitis: S2-guidelines. J Dtsch Dermatol Ges 2009; 7: 1–46. CrossRef MEDLINE
21. Ring J, Alomar A, Bieber T, Deleuran M, et al.: Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol 2012; 26: 1045–60. CrossRef MEDLINE
22. Ring J, Alomar A, Bieber T, Deleuran M, et al.: Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol 2012; 26: 1176–93. CrossRef MEDLINE
23. Dabade TS, Davis DM, Wetter DA, et al.: Wet dressing therapy in conjunction with topical corticosteroids is effective for rapid control of severe pediatric atopic dermatitis: experience with 218 patients over 30 years at Mayo Clinic. J Am Acad Dermatol 2012; 67: 100–6. CrossRef MEDLINE
24.Ehmann LM, Vogel S, Müller-Wiefel S, Wollenberg A: Proaktive Therapie – ein innovatives Langzeittherapiekonzept zur Schubreduktion. Allergologie 2012; 35: 425–32. CrossRef
25. Aubert-Wastiaux H, Moret L, Le Rhun A, et al.: Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. Br J Dermatol 2011; 165: 808–14. CrossRef MEDLINE
26. Siegfried EC, Jaworski JC, Hebert AA. Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. Am J Clin Dermatol 2013; 14: 163–78. CrossRef MEDLINE PubMed Central
27.Czarnecka-Operacz M, Jenerowicz D. Topical calcineurin inhibitors in the treatment of atopic dermatitis—an update on safety issues. J Dtsch Dermatol Ges 2012; 10: 167–72. CrossRef MEDLINE
28. Leinmüller R: Arzneimittelsicherheit: Urteil erst nach Langzeitstudien. Dtsch Arztebl 2012; 109: A-644 / B-558 / C-554 VOLLTEXT
29. Breuer K, Kapp A, Werfel T: Bacterial infections and atopic dermatitis. Allergy 2001; 56: 1034–41. CrossRef MEDLINE
30. Darabi K, Hostetler SG, Bechtel MA, Zirwas M: The role of Malassezia in atopic dermatitis affecting the head and neck of adults. J Am Acad Dermatol 2009; 60: 125–36. CrossRef MEDLINE
31. Sher LG, Chang J, Patel IB, Balkrishnan R, Fleischer AB Jr: Relieving the pruritus of atopic dermatitis: a meta-analysis. Acta Derm Venereol 2012; 92: 455–61. CrossRef MEDLINE
32. Mrowietz U, Klein CE, Reich K, Rosenbach T, Ruzicka T, Sebastian M, Werfel T: Cyclosporine therapy in dermatology. J. Dtsch Dermatol Ges 2009; 7: 474–9. MEDLINE
33. Rockevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J: Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J Allergy Clin Immunol 2014; 133: 429–38. CrossRef MEDLINE
34.Simon D, Bieber T. Systemic therapy for atopic dermatitis. Allergy 2014 69: 46–55. CrossRef MEDLINE
35. Novak N, Bieber T, Hoffmann M, Fölster-Holst R, et al.: Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. J Allergy Clin Immunol 2012; 130: 925–31. CrossRef MEDLINE
36.Bae JM, Choi YY, Park CO, Chung KY, Lee KH: Efficacy of allergen-specific immunotherapy for atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol 2013; 132: 110–7. CrossRef MEDLINE
37. Majoie IM, Oldhoff JM, van Weelden H, et al.: Narrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2009; 60: 77–84. CrossRef MEDLINE
38. Staab D, Diepgen TL, Fartasch M, et al.: Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. BMJ 2006; 332: 933–8. CrossRef MEDLINE PubMed Central
39. Woellner C, Gertz EM, Schäffer AA, et al.: Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome. J Allergy Clin Immunol 2010; 125: 424–32. CrossRef MEDLINE PubMed Central
40. Werfel T, Lotte C, Scheewe S, Staab D: Manual Neurodermitisschulung. München – Orlando: Dustri Verlag Dr. Karl Feistle 2008.
e1.Hoare C, Li Wan Po A, Williams H: Systematic review of treatments for atopic eczema. Health Technol Assess 2000; 4: 1–191. MEDLINE
e2.Tan BB, Weald D, Dawn, Strickland I, Friedmann PS: Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis. Lancet 1996; 347: 15–8. CrossRef MEDLINE
e3. Holm L, Bengtsson A, Hage-Hamsten M, Ohman S, Scheynius A: Effectiveness of occlusive bedding in the treatment of atopic dermatitis – a placebo-controlled trial of 12 months’ duration. Allergy 2001; 56: 152–8. CrossRef MEDLINE
e4. Oosting AJ, De Bruin Weller MS, Terreehorst I, et al.: Effect of mattress encasings on atopic dermatitis outcome measures in a double-blind, placebo-controlled study: The Dutch Mite Avoidance Study. J Allergy Clin Immunol 2002; 110: 500–6. CrossRef MEDLINE
e5. Sampson HA, Gerth van Wijk R, Bindslev-Jensen C, et al.: Standardizing double-blind, placebo-controlled oral food challenges: American Academy of Allergy, Asthma & Immunology-European Academy of Allergy and ClinicalImmunology PRACTALL consensus report. J Allergy Clin Immunol. 2012 130: 1260–74. CrossRef MEDLINE
e6.Grether-Beck S, Felsner I, Brenden H, et al.: Urea uptake enhances barrier function and antimicrobial defense in humans by regulating epidermal gene expression. J Invest Dermatol. 2012 132: 1561–72. CrossRef MEDLINE PubMed Central
e7. Loden M, Andersson AC, Lindberg M: The effect of two urea-containing creams on dry, eczematous skin in atopic patients. II. Adverse effects. J Dermatolog Treat 1999; 10: 171–5. CrossRef
e8. Green C, Colquitt JL, Kirby J, Davidson P: Topical corticosteroids for atopic eczema: clinical and cost effectiveness of once-daily vs. more frequent use. Br J Dermatol 2005; 152: 130–41. CrossRef MEDLINE
e9. Berth-Jones J, Damstra RJ, Golsch S, et al.: Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: Randomised, double blind, parallel group study. BMJ 2003; 326: 1367–70. CrossRef MEDLINE PubMed Central
e10.Hanifin J, Gupta AK, Rajagopalan R, Parker C: Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002; 147: 528–37. CrossRef MEDLINE
e11. Glazenburg EJ, Wolkerstorfer A, Gerretsen AL, Mulder PG, Oranje AP: Efficacy and safety of fluticasone propionate 0.005% ointment in the long-term maintenance treatment of children with atopic dermatitis: differences between boys and girls? Pediatr Allergy Immunol 2009; 20: 59–66. CrossRef MEDLINE
e12. Peserico A, Städtler G, Sebastian M, Fernandez RS, Vick K, Bieber T: Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br J Dermatol 2008; 158: 801–7. CrossRef MEDLINE
e13. Wollenberg A, Reitamo S, Girolomoni G, et al.: Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy 2008; 63: 742–50. CrossRef MEDLINE
e14. Thaçi D, Reitamo S, Gonzalez Ensenat MA, et al.: Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol 2008; 159: 1348–56. CrossRef MEDLINE
e15. Luger T, Van L, Graeber M, Hedgecock S, et al.: SDZ ASM 981: An emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001; 144: 788–94. CrossRef MEDLINE
e16. Luger T, Lahfa M, Folster-Holst R, et al.: Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatolog Treat 2004; 15: 169–78. CrossRef MEDLINE
e17.Garside R, Stein K, Castelnuovo E, Pitt M, Ashcroft D, Dimmock P, Payne L: The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: a systematic review and economic evaluation. Health Technol Assess. 2005; 9(29): iii, xi-xiii, 1–230. MEDLINE
e18. Reitamo S, Ortonne JP, Sand C, et al.: A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2005; 152: 1282–9. CrossRef MEDLINE
e19. Ring J, Möhrenschlager M, Henkel V: The US FDA ’black box’ warning for topical calcineurin inhibitors: an ongoing controversy. Drug Saf 2008; 31: 185–98. CrossRef MEDLINE
e20. Thaçi D, Salgo R: Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies. Clin Dermatol 2010; 28: 52–6. CrossRef MEDLINE
e21. Kim KH, Kono T: Overview of efficacy and safety of tacrolimus ointment in patients with atopic dermatitis in Asia and other areas. Int J Dermatol 2011; 50: 1153–61. CrossRef MEDLINE
e22. Birnie AJ, Bath-Hextall FJ, Ravenscroft JC, Williams HC: Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Cochrane Database Syst Rev 2008 16;(3): CD003871. MEDLINE
e23. Schram ME, Borgonjen RJ, Bik CM, van der Schroeff JG, van Everdingen JJ, Spuls PI; Off-Label Working and Project Group of Dutch Society of Dermatology and Venereology.Off-label use of azathioprine in dermatology: a systematic review. Arch Dermatol 2011; 147: 474–88. MEDLINE
e24. Harskamp CT, Armstrong AW. Immunology of atopic dermatitis: novel insights into mechanisms and immunomodulatory therapies. Semin Cutan Med Surg 2013 32: 132–9 MEDLINE
e25.Schram ME, Roekevisch E, Leeflang MM, Bos JD, Schmitt J, Spuls PI. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol 2011; 128: 353–9. CrossRef MEDLINE
e26. Zoller L, Ramon M, Bergman R. Low dose methotrexate therapy is effective in late-onset atopic dermatitis and idiopathic eczema. Isr Med Assoc J 2008; 10: 413–4. MEDLINE
e27.Al-Herz W, Nanda A: Skin manifestations in primary immunodeficient children. Pediatr Dermatol 2011; 28: 494–501. CrossRef MEDLINE